We are live on ! Find out more
NVS icon

Novartis

1,089 hedge funds and large institutions have $13.7B invested in Novartis in 2022 Q3 according to their latest regulatory filings, with 64 funds opening new positions, 322 increasing their positions, 458 reducing their positions, and 96 closing their positions.

New
Increased
Maintained
Reduced
Closed

116% more call options, than puts

Call options by funds: $441M | Put options by funds: $204M

25% more funds holding in top 10

Funds holding in top 10: 8 → 10 (+2)

0.79% less ownership

Funds ownership: 9.02% → 8.23% (-0.79%)

5% less funds holding

Funds holding: 1,142 → 1,089 (-53)

30% less repeat investments, than reductions

Existing positions increased: 322 | Existing positions reduced: 458

33% less first-time investments, than exits

New positions opened: 64 | Existing positions closed: 96

79% less capital inflows, than outflows

Capital inflows: $424M | Capital outflows: $2.05B

Holders
1,089
Holders Change
-53
Holders Change %
-4.64%
% of All Funds
18.67%
Holding in Top 10
10
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+25%
% of All Funds
0.17%
New
64
Increased
322
Reduced
458
Closed
96
Calls
$441M
Puts
$204M
Net Calls
+$236M
Net Calls Change
+$129M

NVS Hedge Fund Activity: Q3 2022 in Review

1,089 of the 5,834 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q3 2022, worth a combined $13.7B — down 19% from $16.9B a quarter earlier.

Sellers outnumbered buyers: 96 funds closed out of NVS and 64 opened new positions — a net loss of 32 holders — while 458 trimmed existing stakes and 322 added.

The largest buyer was Wellington Management Group, adding an estimated $40M. The largest seller was Fisher Asset Management, cutting an estimated $842M.

  • 1,089 institutional investors held Novartis (NVS) as of Q3 2022, down from 1,142 in Q2 2022.
  • Funds reported $13.7B of Novartis stock for Q3 2022, down 19% quarter-over-quarter.
  • 64 funds opened new Novartis positions in Q3 2022 and 96 closed out, a net change of -32 holders.
  • The largest Novartis buyer in Q3 2022 was Wellington Management Group, an estimated $40M added.
  • The largest Novartis seller in Q3 2022 was Fisher Asset Management, an estimated $842M sold.

Based on aggregated 13F filings for Q3 2022.